Insider · CIK 0001507678

Legorreta Pablo G.

Reports to the SEC for 3 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001507678

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-07	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	Director, CEO, Chairman of the Board	GGift	−30K sh	—	—	662,701
2026-08-05	RPRXRoyalty Pharma plcA Award	Director, CEO, Chairman of the Board	AAward	+65.2K sh	—	—	1,307,820
2026-05-28	PROKPROKIDNEY CORP. · Director stock option (right to buy)A Award	Director, 10% Owner	AAward	+135K sh	—	—	135,000
2026-05-06	RPRXRoyalty Pharma plcA Award	Director, CEO, Chairman of the Board	AAward	+144K sh	—	—	1,242,604
2026-02-11	RPRXRoyalty Pharma plcA Award	Director, CEO, Chairman of the Board	AAward	+158K sh	—	—	1,098,783
2025-11-05	RPRXRoyalty Pharma plcA Award	Director, CEO, Chairman of the Board	AAward	+36.6K sh	—	—	940,955
2025-08-08	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	Director, CEO, Chairman of the Board	GGift	−60K sh	—	—	692,701
2025-08-06	RPRXRoyalty Pharma plcA Award	Director, CEO, Chairman of the Board	AAward	+21.9K sh	—	—	904,396
2025-06-03	PROKPROKIDNEY CORP.C Conversion	Director, 10% Owner	CConversion	+3.82M sh	—	—	26,441,905
2025-06-03	PROKPROKIDNEY CORP.J Other	Director, 10% Owner	JOther	−3.82M sh	—	—	22,617,909
2025-06-03	PROKPROKIDNEY CORP. · Class B Ordinary SharesC Conversion	Director, 10% Owner	CConversion	−3.82M sh	—	—	84,283,430
2025-06-03	PROKPROKIDNEY CORP. · Common Units in ProKidney LPC Conversion	Director, 10% Owner	CConversion	−3.82M sh	—	—	84,283,430
2025-05-29	PROKPROKIDNEY CORP. · Director stock option (right to buy)A Award	Director, 10% Owner	AAward	+126K sh	—	—	125,862
2025-05-16	RPRXRoyalty Pharma plcJ Other	Director, CEO, Chairman of the Board	JOther	+530K sh	—	—	882,495
2025-05-16	RPRXRoyalty Pharma plc · Class E Ordinary SharesA Award	Director, CEO, Chairman of the Board	AAward	+13.4M sh	—	—	13,356,742
2025-05-16	RPRXRoyalty Pharma plc · Option (Right to Buy)J Other	Director, CEO, Chairman of the Board	JOther	+857K sh	—	—	857,138
2025-05-12	RPRXRoyalty Pharma plc · Class B Ordinary SharesG Gift	Director, CEO, Chairman of the Board	GGift	−867K sh	—	—	0
2025-05-12	RPRXRoyalty Pharma plc · Class B Ordinary SharesG Gift	Director, CEO, Chairman of the Board	GGift	+867K sh	—	—	0
2025-05-08	RPRXRoyalty Pharma plcA Award	Director, CEO, Chairman of the Board	AAward	+288K sh	—	—	352,147
2025-02-04	PROKPROKIDNEY CORP.C Conversion	Director, 10% Owner	CConversion	+533K sh	—	—	23,150,444
2025-02-04	PROKPROKIDNEY CORP.J Other	Director, 10% Owner	JOther	−533K sh	—	—	22,617,909
2025-02-04	PROKPROKIDNEY CORP. · Class B Ordinary SharesC Conversion	Director, 10% Owner	CConversion	−533K sh	—	—	88,107,426
2025-02-04	PROKPROKIDNEY CORP. · Common Units in ProKidney LPC Conversion	Director, 10% Owner	CConversion	−533K sh	—	—	88,107,426
2024-06-13	PROKPROKIDNEY CORP.P Purchase	Director, 10% Owner	PPurchase	+22.6M sh	$2.42	+$54.7M	22,617,909
2024-05-30	PROKPROKIDNEY CORP. · Director stock option (right to buy)A Award	Director, 10% Owner	AAward	+62.6K sh	—	—	62,558
2024-02-05	PROKPROKIDNEY CORP.C Conversion	Director, 10% Owner	CConversion	+749K sh	—	—	748,952
2024-02-05	PROKPROKIDNEY CORP.J Other	Director, 10% Owner	JOther	−749K sh	—	—	0
2024-02-05	PROKPROKIDNEY CORP. · Class B Ordinary SharesC Conversion	Director, 10% Owner	CConversion	−749K sh	—	—	88,639,961
2024-02-05	PROKPROKIDNEY CORP. · Common Units in ProKidney LPC Conversion	Director, 10% Owner	CConversion	−749K sh	—	—	88,639,961
2023-11-16	RPRXRoyalty Pharma plcJ Other	Director, CEO, Chairman of the Board	JOther	−383K sh	—	—	63,795
2023-10-30	PROKPROKIDNEY CORP.C Conversion	Director, 10% Owner	CConversion	+5.29M sh	—	—	5,289,055
2023-10-30	PROKPROKIDNEY CORP.J Other	Director, 10% Owner	JOther	−5.29M sh	—	—	0
2023-10-30	PROKPROKIDNEY CORP. · Class B Ordinary SharesC Conversion	Director, 10% Owner	CConversion	−5.29M sh	—	—	89,388,913
2023-10-30	PROKPROKIDNEY CORP. · Common Units in ProKidney LPC Conversion	Director, 10% Owner	CConversion	−5.29M sh	—	—	89,388,913
2023-06-29	PROKPROKIDNEY CORP. · Director stock option (right to buy)A Award	Director, 10% Owner	AAward	+48.1K sh	—	—	48,128
2023-06-28	RPRXRoyalty Pharma plcP Purchase	Director, CEO, Chairman of the Board	PPurchase	+130K sh	$29.51	+$3.84M	600,000
2023-06-13	RPRXRoyalty Pharma plcP Purchase	Director, CEO, Chairman of the Board	PPurchase	+45K sh	$32.78	+$1.47M	470,000
2023-06-12	RPRXRoyalty Pharma plcP Purchase	Director, CEO, Chairman of the Board	PPurchase	+45K sh	$33.00	+$1.48M	425,000
2023-05-24	RPRXRoyalty Pharma plcP Purchase	Director, CEO, Chairman of the Board	PPurchase	+150K sh	$32.25	+$4.84M	380,000
2023-05-17	RPRXRoyalty Pharma plcP Purchase	Director, CEO, Chairman of the Board	PPurchase	+69.6K sh	$32.94	+$2.29M	230,000
2023-05-16	RPRXRoyalty Pharma plcP Purchase	Director, CEO, Chairman of the Board	PPurchase	+160K sh	$33.57	+$5.38M	160,388
2023-05-12	RPRXRoyalty Pharma plc · ICAI InterestsG Gift	Director, CEO, Chairman of the Board	GGift	−10.3K sh	—	—	0
2023-05-12	RPRXRoyalty Pharma plc · ICAI InterestsG Gift	Director, CEO, Chairman of the Board	GGift	+10.3K sh	—	—	692,701
2022-12-30	RPRXRoyalty Pharma plcG Gift	Director, CEO, Chairman of the Board	GGift	+292K sh	—	—	292,190.49
2022-08-12	Epizyme, Inc.U Disposition from Tender	Director, 10% Owner	UDisposition from Tender	−31.9M sh	—	—	0
2022-08-12	Epizyme, Inc.Restricted Stock UnitsD Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−8,060 sh	—	—	0
2022-08-12	Epizyme, Inc.Restricted Stock UnitsD Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−8,994 sh	—	—	0
2022-08-12	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	Director, CEO, Chairman of the Board	GGift	−151K sh	—	—	2,700,000
2022-07-11	PROKPROKIDNEY CORP. · Class B Ordinary SharesA Award	Director, 10% Owner	AAward	+94.7M sh	—	—	94,677,968
2022-07-11	PROKPROKIDNEY CORP. · Common Units in ProKidney LPA Award	Director, 10% Owner	AAward	+94.7M sh	—	—	94,677,968

Recent filings

Accepted (ET)
Aug 74
Legorreta Pablo G.0001507678-26-000006
SEC(opens sec.gov)
May 294
Legorreta Pablo G.0001193125-26-248221
SEC(opens sec.gov)
May 84
Legorreta Pablo G.0001507678-26-000004
SEC(opens sec.gov)
Feb 134
Legorreta Pablo G.0001507678-26-000002
SEC(opens sec.gov)
Nov 74
Legorreta Pablo G.0001507678-25-000010
SEC(opens sec.gov)
Aug 84
Legorreta Pablo G.0001802768-25-000105
SEC(opens sec.gov)
Jun 54
Legorreta Pablo G.0000950170-25-082342
SEC(opens sec.gov)
Jun 24
Legorreta Pablo G.0000950170-25-080277
SEC(opens sec.gov)
May 204
Legorreta Pablo G.0001802768-25-000063
SEC(opens sec.gov)
May 144
Legorreta Pablo G.0001802768-25-000043
SEC(opens sec.gov)
May 94
Legorreta Pablo G.0001802768-25-000039
SEC(opens sec.gov)
Feb 64
Legorreta Pablo G.0000950170-25-015495
SEC(opens sec.gov)

Companies

Address

C/O ROYALTY PHARMA PLC 110 E. 59TH STREET

NEW YORK, NY, 10022